International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer

Breast

Volumn 22, Issue 3, 2013, Pages 203-210

  Lin, Nancy U ^a   Thomssen, Christoph ^b   Cardoso, Fatima ^c   Cameron, David ^d   Cufer, Tanja ^e   Fallowfield, Lesley ^f   Francis, Prudence A ^g   Kyriakides, Stella ^h   Pagani, Olivia ⁱ   Senkus, Elzbieta ^j   Costa, Alberto ^k,l   Winer, Eric P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c Champalimaud Cancer Center   (Portugal)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^f UNIVERSITY OF SUSSEX   (United Kingdom)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h Europa Donna Cyprus   (Cyprus)

ⁱ OSPEDALE SAN GIOVANNI   (Switzerland)

^j MEDICAL UNIVERSITY OF GDANSK   (Poland)

^k EUROPEAN SCHOOL OF ONCOLOGY   (Italy)

^l IRCCS   (Italy)

more..

Author keywords

ABC; Breast cancer; Evaluation; Follow up; Guidelines; Staging; Surveillance

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; LAPATINIB; MESSENGER RNA; MICRORNA; TRASTUZUMAB; TUMOR MARKER;

ANAMNESIS; BLOOD ANALYSIS; BONE METASTASIS; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FALSE POSITIVE RESULT; FOLLOW UP; GENE EXPRESSION PROFILING; HEALTH CARE NEED; HUMAN; KARNOFSKY PERFORMANCE STATUS; LABORATORY TEST; MAMMOGRAPHY; MEDICAL DECISION MAKING; NEEDS ASSESSMENT; OUTCOME ASSESSMENT; PATIENT MONITORING; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84877147107     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.03.006     Document Type: Review

References (71)

1. Keating N.L., Landrum M.B., Guadagnoli E., Winer E.P., Ayanian J.Z. Surveillance testing among survivors of early-stage breast cancer. JClin Oncol 2007, 25(9):1074-1081.
2. Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. Breast (Edinburgh, Scotland) 2007, 16(1):9-10.
3. Cardoso F., Bedard P.L., Winer E.P., Pagani O., Senkus-Konefka E., Fallowfield L.J., et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. JNatl Cancer Inst 2009, 101(17):1174-1181.
4. Pagani O., Senkus E., Wood W., Colleoni M., Cufer T., Kyriakides S., et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?. JNatl Cancer Inst 2010, 102(7):456-463.
5. de Bock G.H., Bonnema J., Zwaan R.E., van de Velde C.J., Kievit J., Stiggelbout A.M. Patient's needs and preferences in routine follow-up after treatment for breast cancer. Br J Cancer 2004, 90(6):1144-1150.
6. Loprinzi C.L., Hayes D., Smith T. Doc, shouldn't we be getting some tests?. JClin Oncol 2003, 21(9 Suppl.):108s-111s.
7. Muss H.B., Tell G.S., Case L.D., Robertson P., Atwell B.M. Perceptions of follow-up care in women with breast cancer. Am J Clin Oncol 1991, 14(1):55-59.
8. Hillner B.E., McDonald M.K., Penberthy L., Desch C.E., Smith T.J., Maddux P., et al. Measuring standards of care for early breast cancer in an insured population. JClin Oncol 1997, 15(4):1401-1408.
9. Simon M.S., Stano M., Hussein M., Hoff M., Smith D. An analysis of the cost of clinical surveillance after primary therapy for women with early stage invasive breast cancer. Breast Cancer Res Treat 1996, 37(1):39-48.
10. Grunfeld E., Hodgson D.C., Del Giudice M.E., Moineddin R. Population-based longitudinal study of follow-up care for breast cancer survivors. JOncol Pract/Am Soc Clin Oncol 2010, 6(4):174-181.
11. Mille D., Roy T., Carrere M.O., Ray I., Ferdjaoui N., Spath H.M., et al. Economic impact of harmonizing medical practices: compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center. JClin Oncol 2000, 18(8):1718-1724.
12. Kokko R., Hakama M., Holli K. Follow-up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Res Treat 2005, 93(3):255-260.
13. Mapelli V., Dirindin N., Grilli R. Economic evaluation of diagnostic follow-up after primary treatment for breast cancer. Results of the Working Group on Economic-Organizational Aspects of Follow-up. Ann Oncol 1995, 6(Suppl. 2):61-64.
14. Simon M.S., Stano M., Severson R.K., Hoff M.S., Smith D.W. Clinical surveillance for early stage breast cancer: an analysis of claims data. Breast Cancer Res Treat 1996, 40(2):119-128.
15. Kroenke C.H., Chen W.Y., Rosner B., Holmes M.D. Weight, weight gain, and survival after breast cancer diagnosis. JClin Oncol 2005, 23(7):1370-1378.
16. Pierce J.P., Natarajan L., Caan B.J., Parker B.A., Greenberg E.R., Flatt S.W., et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAm Med Assoc 2007, 298(3):289-298.
17. Obedian E., Fischer D.B., Haffty B.G. Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy. JClin Oncol 2000, 18(12):2406-2412.
18. Lu W., de Bock G.H., Schaapveld M., Baas P.C., Wiggers T., Jansen L. The value of routine physical examination in the follow up of women with a history of early breast cancer. Eur J Cancer 2011, 47(5):676-682.
19. Houssami N., Abraham L.A., Miglioretti D.L., Sickles E.A., Kerlikowske K., Buist D.S., et al. Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. JAm Med Assoc 2011, 305(8):790-799.
20. de Bock G.H., Bonnema J., van der Hage J., Kievit J., van de Velde C.J. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. JClin Oncol 2004, 22(19):4010-4018.
21. Lu W.L., Jansen L., Post W.J., Bonnema J., Van de Velde J.C., De Bock G.H. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat 2009, 114(3):403-412.
22. Montgomery D.A., Krupa K., Cooke T.G. Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer 2007, 97(12):1632-1641.
23. van der Sangen M.J., Scheepers S.W., Poortmans P.M., Luiten E.J., Nieuwenhuijzen G.A., Voogd A.C. Detection of local recurrence following breast-conserving treatment in young women with early breast cancer: optimization of long-term follow-up strategies. Breast (Edinburgh, Scotland) 2012, Sep 15. pii: S0960-9776(12)00186-5. http://dx.doi.org/10.1016/j.breast.2012.08.006. [Epub ahead of print].
24. Lu W., Schaapveld M., Jansen L., Bagherzadegan E., Sahinovic M.M., Baas P.C., et al. The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer. Eur J Cancer 2009, 45(17):3000-3007.
25. Saslow D., Boetes C., Burke W., Harms S., Leach M.O., Lehman C.D., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57(2):75-89.
26. Rosselli Del Turco M., Palli D., Cariddi A., Ciatto S., Pacini P., Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAm Med Assoc 1994, 271(20):1593-1597.
27. Palli D., Russo A., Saieva C., Ciatto S., Rosselli Del Turco M., Distante V., et al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer follow-up. JAm Med Assoc 1999, 281(17):1586.
28. GIVIO Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAm Med Assoc 1994, 271(20):1587-1592.
29. Rojas M.P., Telaro E., Russo A., Moschetti I., Coe L., Fossati R., et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev (Online) 2005, (1). CD001768.
30. Rutgers E.J., van Slooten E.A., Kluck H.M. Follow-up after treatment of primary breast cancer. Br J Surg 1989, 76(2):187-190.
31. Pandya K.J., McFadden E.T., Kalish L.A., Tormey D.C., Taylor SGt, Falkson G. Aretrospective study of earliest indicators of recurrence in patients on Eastern Cooperative Oncology Group adjuvant chemotherapy trials for breast cancer. A preliminary report. Cancer 1985, 55(1):202-205.
32. Joseph E., Hyacinthe M., Lyman G.H., Busch C., Demps L., Reintgen D.S., et al. Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Ann Surg Oncol 1998, 5(6):522-528.
33. Lumachi F., Brandes A.A., Boccagni P., Polistina F., Favia G., D'Amico D.F. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Anticancer Res 1999, 19(5C):4485-4489.
34. Brenner D.J., Doll R., Goodhead D.T., Hall E.J., Land C.E., Little J.B., et al. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A 2003, 100(24):13761-13766.
35. Brenner D.J., Elliston C.D. Estimated radiation risks potentially associated with full-body CT screening. Radiology 2004, 232(3):735-738.
36. Kokko R., Holli K., Hakama M. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer 2002, 38(9):1189-1193.
37. Chan D.W., Beveridge R.A., Muss H., Fritsche H.A., Hortobagyi G., Theriault R., et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. JClin Oncol 1997, 15(6):2322-2328.
38. Chia S.K., Speers C.H., D'Yachkova Y., Kang A., Malfair-Taylor S., Barnett J., et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007, 110(5):973-979.
39. Khatcheressian J.L., Wolff A.C., Smith T.J., Grunfeld E., Muss H.B., Vogel V.G., et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. JClin Oncol 2006, 24(31):5091-5097.
40. Kataja V., Castiglione M. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):10-14.
41. Hillner B.E., Ingle J.N., Chlebowski R.T., Gralow J., Yee G.C., Janjan N.A., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. JClin Oncol 2003, 21(21):4042-4057.
42. NCCN clinical practice guidlines in oncology 2013.
43. Schnipper L.E., Smith T.J., Raghavan D., Blayney D.W., Ganz P.A., Mulvey T.M., et al. American society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. JClin Oncol 2012, 30(14):1715-1724.
44. Giordano S.H., Buzdar A.U., Smith T.L., Kau S.W., Yang Y., Hortobagyi G.N. Is breast cancer survival improving?. Cancer 2004, 100(1):44-52.
45. Cardoso F., Senkus-Konefka E., Fallowfield L.J., Costa A., Castiglione M. Clinical practice guidelines: locally recurrent or metastatic breast cancer: ESMO clinical practice guidlines for diagnosis, treatment, and follow-up. Ann Oncol 2010, 21:15-19.
46. Thomssen C., Scharl A., Harbeck N. AGO Recommendations for diagnosis and treatment of patients with primary and metastatic breast cancer. Update 2011. Breast Care (Basel) 2011, 6(4):299-313. www.ago-online.de(download 02/Apr/2013).
47. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. JClin Oncol 2007, 25(33):5287-5312.
48. Cardoso F., Costa A., Norton L., Cameron D., Cufer T., Fallowfield L., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (Edinburgh, Scotland) 2012, 21:242-252.
49. Khasraw M., Brogi E., Seidman A.D. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?. Curr Oncol Rep 2011, 13(1):17-25.
50. Thompson A.M., Jordan L.B., Quinlan P., Anderson E., Skene A., Dewar J.A., et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 2010, 12(6):R92.
51. Andersson M., Madsen E.L., Overgaard M., Rose C., Dombernowsky P., Mouridsen H.T. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer - a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1999, 35(1):39-46.
52. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247.
53. Drotman M.B., Machnicki S.C., Schwartz L.H., Winston C.B., Yoo H.H., Panicek D.M. Breast cancer: assessing the use of routine pelvic CT in patient evaluation. Am J Roentgenol 2001, 176(6):1433-1436.
54. Constantinidou A., Martin A., Sharma B., Johnston S.R. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol 2011, 22(2):307-314.
55. Auguste P., Barton P., Hyde C., Roberts T.E. An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess (Winchester, England) 2011, 15(18):iii-iiv. 1-54.
56. Mahner S., Schirrmacher S., Brenner W., Jenicke L., Habermann C.R., Avril N., et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-d-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 2008, 19(7):1249-1254.
57. Dehdashti F., Mortimer J.E., Trinkaus K., Naughton M.J., Ellis M., Katzenellenbogen J.A., et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 2009, 113(3):509-517.
58. Ellis M.J., Gao F., Dehdashti F., Jeffe D.B., Marcom P.K., Carey L.A., et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAm Med Assoc 2009, 302(7):774-780.
59. Forero-Torres A., Saleh M.N., Galleshaw J.A., Jones C.F., Shah J.J., Percent I.J., et al. Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. Clin Breast Cancer 2010, 10(4):275-280.
60. Shie P., Cardarelli R., Brandon D., Erdman W., Abdulrahim N. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med 2008, 33(2):97-101.
61. Costelloe C.M., Rohren E.M., Madewell J.E., Hamaoka T., Theriault R.L., Yu T.K., et al. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 2009, 10(6):606-614.
62. De Giorgi U., Mego M., Rohren E.M., Liu P., Handy B.C., Reuben J.M., et al. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. JNucl Med 2010, 51(8):1213-1218.
63. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. NEngl J Med 2004, 351(8):781-791.
64. Pierga J.Y., Hajage D., Bachelot T., Delaloge S., Brain E., Campone M., et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012, 23(3):618-624.
65. Liu M.C., Shields P.G., Warren R.D., Cohen P., Wilkinson M., Ottaviano Y.L., et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. JClin Oncol 2009, 27(31):5153-5159.
66. Hartkopf A.D., Wagner P., Wallwiener D., Fehm T., Rothmund R. Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res 2011, 31(3):979-984.
67. Gradilone A., Naso G., Raimondi C., Cortesi E., Gandini O., Vincenzi B., et al. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann Oncol 2011, 22(1):86-92.
68. Flores L.M., Kindelberger D.W., Ligon A.H., Capelletti M., Fiorentino M., Loda M., et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer 2010, 102(10):1495-1502.
69. Sieuwerts A.M., Mostert B., Bolt-de Vries J., Peeters D., de Jongh F.E., Stouthard J.M., et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 2011, 17(11):3600-3618.
70. Munzone E., Nole F., Goldhirsch A., Botteri E., Esposito A., Zorzino L., et al. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer 2010, 10(5):392-397.
71. Mayer M., Hunis A., Oratz R., Glennon C., Spicer P., Caplan E., et al. Living with metastatic breast cancer: a global patient survey. Community Oncol 2010, 7(9):406-412.